
This article is brought to you in association with the European Commission. The European Commission has fined Teva €462.6 million for abusing its dominant position to delay competition to its blockbuster medicine for the treatment of multiple sclerosis, Copaxone. The Commission found that Teva artificially extended the patent protection of Copaxone and systematically spread misleading information […]


















